Hikma reaches settlement in US pay-for-delay litigation over Xyrem drug
MLex Summary: Class plaintiffs requested a US judge to preliminary approve a settlement with Hikma, the last defendant in litigation that accused pharmaceutical companies of engaging in an anticompetitive scheme to delay...To view the full article, register now.
Already a subscriber? Click here to view full article